{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T17:38:03Z","timestamp":1769189883880,"version":"3.49.0"},"reference-count":50,"publisher":"Impact Journals, LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,1,31]]},"DOI":"10.18632\/oncotarget.13951","type":"journal-article","created":{"date-parts":[[2016,12,19]],"date-time":"2016-12-19T14:19:58Z","timestamp":1482157198000},"page":"7777-7790","source":"Crossref","is-referenced-by-count":9,"title":["The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR\/ABL and T315I mutant BCR\/ABL through promoting proteosomal degradation of BCR\/ABL proteins"],"prefix":"10.18632","volume":"8","author":[{"given":"Liangshun","family":"You","sequence":"first","affiliation":[{"name":"Institute of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[{"name":"Institute of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fourth Affiliated Hospital, College of Medicine, Zhejiang University, Yiwu 322000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanzhuo","family":"Xie","sequence":"additional","affiliation":[{"name":"Institute of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jueying","family":"Wei","sequence":"additional","affiliation":[{"name":"Institute of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiujin","family":"Ye","sequence":"additional","affiliation":[{"name":"Institute of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbin","family":"Qian","sequence":"additional","affiliation":[{"name":"Institute of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,12,15]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","article-title":"Translation of the Philadelphia chromosome into therapy for CML","volume":"112","author":"Druker","year":"2008","journal-title":"Blood"},{"key":"2","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Boqu\u00e9","year":"2010","journal-title":"N Engl J Med"},{"key":"3","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Dong","year":"2010","journal-title":"N Engl J Med"},{"key":"4","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Druker","year":"2005","journal-title":"Blood"},{"key":"5","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Powell","year":"2006","journal-title":"N Engl J Med"},{"key":"6","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Sawyers","year":"2001","journal-title":"Science"},{"key":"7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2005-07-2815","article-title":"BCR\/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance","volume":"108","author":"Skorski","year":"2006","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"Marin","year":"2008","journal-title":"J Clin Oncol"},{"key":"9","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1634\/theoncologist.2010-0388","article-title":"Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC50?","volume":"16","author":"Martinelli","year":"2011","journal-title":"Oncologist"},{"key":"10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Holyoake","year":"2002","journal-title":"Blood"},{"key":"11","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","article-title":"Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells","volume":"109","author":"Holyoake","year":"2007","journal-title":"Blood"},{"key":"12","doi-asserted-by":"crossref","first-page":"9624","DOI":"10.1158\/0008-5472.CAN-08-1131","article-title":"Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells","volume":"68","author":"Bhatia","year":"2008","journal-title":"Cancer Res"},{"key":"13","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1073\/pnas.0602402103","article-title":"Loss of p53 impedes the antileukemic response to BCR-ABL inhibition","volume":"103","author":"Lowe","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrclinonc.2010.174","article-title":"Translating p53 into the clinic","volume":"8","author":"Lane","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"15","doi-asserted-by":"crossref","first-page":"6293","DOI":"10.1073\/pnas.88.14.6293","article-title":"p53 in chronic myelogenous leukemia in acute phase","volume":"88","author":"Canaani","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"16","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood.V75.1.180.bloodjournal751180","article-title":"Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia","volume":"75","author":"Deisseroth","year":"1990","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1535-6108(03)00020-5","article-title":"BCR\/ABL activates mdm2 mRNA translation via the La antigen","volume":"3","author":"Perrotti","year":"2003","journal-title":"Cancer Cell"},{"key":"18","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s10495-010-0457-0","article-title":"Enhancement of imatinib-induced apoptosis of BCR\/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway","volume":"15","author":"Miura","year":"2010","journal-title":"Apoptosis"},{"key":"19","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/leu.2011.7","article-title":"p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells","volume":"25","author":"Talpaz","year":"2011","journal-title":"Leukemia"},{"key":"20","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1158\/1535-7163.MCT-10-0337","article-title":"The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias","volume":"9","author":"Andreeff","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1756-8722-4-16","article-title":"Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP","volume":"4","author":"Mirshahidi","year":"2011","journal-title":"J Hematol Oncol"},{"key":"22","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1158\/1078-0432.CCR-11-1101","article-title":"A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors","volume":"17","author":"Zhuang","year":"2011","journal-title":"Clin Cancer Res"},{"key":"23","doi-asserted-by":"crossref","first-page":"e74741","DOI":"10.1371\/journal.pone.0074741","article-title":"Serdemetan antagonizes the Mdm2-HIF1\u03b1 axis leading to decreased levels of glycolytic enzymes","volume":"8","author":"Mayo","year":"2013","journal-title":"PLoS One"},{"key":"24","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/pbc.23319","article-title":"Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program","volume":"59","author":"Janicot","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"285","key":"25","first-page":"1733","article-title":"A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy","volume":"1999","author":"Gudkov","journal-title":"Science"},{"issue":"303","key":"26","first-page":"844","article-title":"In vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"2004","author":"Liu","journal-title":"Science"},{"key":"27","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.18632\/oncotarget.806","article-title":"STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia","volume":"3","author":"Sexl","year":"2012","journal-title":"Oncotarget"},{"key":"28","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0301-472X(01)00787-1","article-title":"Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells","volume":"30","author":"Hiddemann","year":"2002","journal-title":"Exp Hematol"},{"key":"29","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ccr.2011.03.003","article-title":"Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036","volume":"19","author":"Smith","year":"2011","journal-title":"Cancer Cell"},{"key":"30","doi-asserted-by":"publisher","first-page":"713","DOI":"10.18632\/oncotarget.333","article-title":"Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy","volume":"2","author":"Turhan","year":"2011","journal-title":"Oncotarget"},{"key":"31","first-page":"3127","article-title":"The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210 Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells","volume":"60","author":"Wu","year":"2000","journal-title":"Cancer Res"},{"key":"32","first-page":"7149","article-title":"Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571)","volume":"62","author":"Druker","year":"2002","journal-title":"Cancer Res"},{"key":"33","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1158\/1078-0432.CCR-08-2141","article-title":"Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation","volume":"15","author":"Pan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"34","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"113","author":"Cortes","year":"2009","journal-title":"Blood"},{"key":"35","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","article-title":"The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein","volume":"8","author":"Bruner-Klisovic","year":"2005","journal-title":"Cancer Cell"},{"key":"36","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrc3430","article-title":"MDM2, MDMX and p53 in oncogenesis and cancer therapy","volume":"13","author":"Wahl","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"37","doi-asserted-by":"crossref","first-page":"21683","DOI":"10.1073\/pnas.1016311108","article-title":"As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia","volume":"107","author":"Chen","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"38","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1182\/blood-2010-03-276477","article-title":"Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis","volume":"117","author":"Donato","year":"2011","journal-title":"Blood"},{"key":"39","first-page":"5126","article-title":"Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abland induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells","volume":"63","author":"Bhalla","year":"2003","journal-title":"Cancer Res"},{"key":"40","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/sj.bjc.6603317","article-title":"ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia","volume":"95","author":"Neviani","year":"2006","journal-title":"Br J Cancer"},{"key":"41","doi-asserted-by":"crossref","first-page":"6660","DOI":"10.1182\/blood-2010-08-304477","article-title":"Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression","volume":"117","author":"Clark","year":"2011","journal-title":"Blood"},{"key":"42","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1172\/JCI68951","article-title":"PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells","volume":"123","author":"Zhang","year":"2013","journal-title":"J Clin Invest"},{"key":"43","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1126\/science.1189749","article-title":"Cancer therapy reform","volume":"328","author":"Levinson","year":"2010","journal-title":"Science"},{"key":"44","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Abruzzese","year":"2013","journal-title":"N Engl J Med"},{"key":"45","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.18632\/oncotarget.692","article-title":"All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib","volume":"3","author":"Lenain","year":"2012","journal-title":"Oncotarget"},{"key":"46","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/aps.2011.192","article-title":"Perifosine induces protective autophagy and upregulation of ATG5 in human chronic myelogenous leukemia cells in vitro","volume":"33","author":"Qian","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"47","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.canlet.2009.09.006","article-title":"Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation","volume":"290","author":"Pan","year":"2010","journal-title":"Cancer Lett"},{"key":"48","doi-asserted-by":"crossref","first-page":"6293","DOI":"10.1073\/pnas.88.14.6293","article-title":"p53 in chronic myelogenous leukemia in acute phase","volume":"88","author":"Canaani","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1756-8722-6-18","article-title":"SNS-032 inhibits mTORC1\/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt","volume":"6","author":"Qian","year":"2013","journal-title":"J Hematol Oncol"},{"key":"50","doi-asserted-by":"crossref","first-page":"20858","DOI":"10.1074\/jbc.M310643200","article-title":"The pro-apoptotic protein Bim is a convergence point for cAMP\/protein kinase A- and glucocorticoid-promoted apoptosis of lymphoid cells","volume":"279","author":"Insel","year":"2004","journal-title":"J Biol Chem"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13951","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T16:03:55Z","timestamp":1589126635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,15]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,1,31]]}},"alternative-id":["13951","27999193"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.13951","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,15]]}}}